Why Are Moderna Executives Dumping Their Stock?

Analysis by Dr. Joseph Mercola

September 21, 2020


Story at-a-glance


  • Results from Moderna’s Phase 1 human trial revealed the 100-mcg dose vaccine — which had a 100% side effect ratio after the second dose — is proceeding to Phase 3 trial assessment
  • Moderna has no legal rights to a key patent for its vaccine delivery system. Moderna sought to invalidate the patent for lipid nanotechnology owned by Arbutus Biopharma but lost the challenge at the end of July 2020
  • Executives at Moderna have cashed in stock options, raking in about $90 million in personal profits since January. Two Moderna executives have now sold off all of their stock holdings in the company, and its general counsel has sold nearly all of hers
  • AstraZeneca has temporarily halted its Phase 3 vaccine trials due to “a suspected serious and unexpected adverse reaction” in a British participant
  • AstraZeneca did not divulge the nature of the adverse reaction, but an anonymous source claims the trial participant was found to have transverse myelitis, an inflammatory condition that affects the spinal cord and is frequently triggered by viral infections
The U.S. Health and Human Services' Operation Warp Speed has pledged to deliver 300 million doses of a COVID-19 vaccine by 2021, if not sooner. However, developing a safe and effective vaccine normally takes years and begins with animal studies. The COVID-19 vaccines are all being rushed straight into human clinical tests, forgoing lengthy animal trials altogether.

Such fast-tracked vaccines pose unknown risks, which are further magnified since governments are granting COVID-19 vaccine makers immunity from liability for all vaccine injuries and deaths that occur after the vaccines are recommended (or mandated) by public health officials.

At the end of July 2020, AstraZeneca announced most countries it expects to supply with COVID-19 vaccine will grant the pharmaceutical company complete liability protection if people are harmed.

In the U.S., vaccine makers already have something of a "free pass" when it comes to vaccine injury liability and lawsuits through the National Childhood Vaccine Injury Act of 1986 and the Public Readiness and Emergency Preparedness (PREP) Act, passed in 2005.

The main concern is that the combination of COVID-19 vaccines being fast-tracked to market at "warp speed" with minimal testing, together with blanket liability protection against vaccine injuries could be a public health nightmare in the making.

Problems With Moderna’s Vaccine Are Becoming Apparent

Early warning signs that something might be amiss have already started emerging. As detailed in “Gates Tries to Justify Side Effects of Fast-Tracked Vaccine,” results from Moderna’s Phase 1 human trial revealed 100% of volunteers in the high-dose group suffered systemic side effects. Side effects included fatigue, chills, headache and myalgia (muscle pain); 21% suffered “one or more severe events.”

According to Bill Gates, those side effects are largely due to the high dosages Moderna had to use in order to achieve desired antibody levels. But, if high dosages are required to create a robust-enough immune response, and higher dosages also cause systemic side effects in nearly all people, just how safe will this vaccination campaign be?

In July, it was reported that the 100-mcg dose vaccine — despite its 100% side effect ratio after the second dose — would proceed to Phase 3 trial assessment. In a May 26, 2020, article in STAT news, Ian Haydon, one of the Phase 1 study participants who suffered severe side effects requiring hospitalization, stated that while he recovered, the inoculation left him feeling “as sick as he’d ever felt.” As noted by Robert F. Kennedy Jr.:


“Three of the 15 human guinea pigs in the high dose cohort (250 mcg) suffered a ‘serious adverse event’ within 43 days of receiving Moderna’s jab. Moderna … acknowledged that three volunteers developed Grade 3 systemic events defined by the FDA as ‘Preventing daily activity and requiring medical intervention.’

Moderna allowed only exceptionally healthy volunteers to participate in the study. A vaccine with those reaction rates could cause grave injuries in 1.5 billion humans if administered to ‘every person on earth.’ That is the threshold that Gates has established for ending the global lockdown.

Moderna did not explain why it reported positive antibody tests for only eight participants. These outcomes are particularly disappointing because the most hazardous hurdle for the inoculation is still ahead; challenging participants with wild COVID infection.

Past attempts at developing COVID vaccines have always faltered at this stage as both humans and animals achieved robust antibody response then sickened and died when exposed to the wild virus.”